Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

F Smits; K Groen; MD Levin; C Stege; RJW Van Kampen; E Van der Spek; YM Bilgin; N Thielen; IS Nijhof; I Ludwig; EGM De Waal; Y Sandberg; A Kentos; GJ Timmers; JC Regelink; M Westerman; K de Heer; MC Vekemans; N Durdu-Rayman; N de Graauw; MR Seefat; NWCJ van de Donk; PF Ypma; K Nasserinejad; S Zweegman

doi:10.1182/blood-2023-180006

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

F Smits, K Groen, MD Levin, C Stege, RJW Van Kampen, E Van der Spek, YM Bilgin, N Thielen, IS Nijhof, I Ludwig, EGM De Waal, Y Sandberg, A Kentos, GJ Timmers, JC Regelink, M Westerman, K de Heer, MC Vekemans, N Durdu-Rayman, N de GraauwMR Seefat, NWCJ van de Donk, PF Ypma, K Nasserinejad, S Zweegman

Hematology

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

2 Citations (Web of Science)

13 Downloads (Pure)

Abstract

The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories ‘fit’, ‘intermediate-fit’ or ‘frail’. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study.

Original language	English
Number of pages	5
Journal	Blood
Volume	142
Issue number	Supplement 1 - 342
DOIs	https://doi.org/10.1182/blood-2023-180006
Publication status	Published - 28 Nov 2023

Access to Document

10.1182/blood-2023-180006

blood-4946-mainFinal published version, 436 KB

Cite this

Smits, F., Groen, K., Levin, MD., Stege, C., Van Kampen, RJW., Van der Spek, E., Bilgin, YM., Thielen, N., Nijhof, IS., Ludwig, I., De Waal, EGM., Sandberg, Y., Kentos, A., Timmers, GJ., Regelink, JC., Westerman, M., de Heer, K., Vekemans, MC., Durdu-Rayman, N., ... Zweegman, S. (2023). Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study. Blood, 142(Supplement 1 - 342). https://doi.org/10.1182/blood-2023-180006

@article{967e04bf94b44fdc9099692e58b238b5,

title = "Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study",

abstract = "The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories {\textquoteleft}fit{\textquoteright}, {\textquoteleft}intermediate-fit{\textquoteright} or {\textquoteleft}frail{\textquoteright}. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study.",

author = "F Smits and K Groen and MD Levin and C Stege and {Van Kampen}, RJW and {Van der Spek}, E and YM Bilgin and N Thielen and IS Nijhof and I Ludwig and {De Waal}, EGM and Y Sandberg and A Kentos and GJ Timmers and JC Regelink and M Westerman and {de Heer}, K and MC Vekemans and N Durdu-Rayman and {de Graauw}, N and MR Seefat and {van de Donk}, NWCJ and PF Ypma and K Nasserinejad and S Zweegman",

year = "2023",

month = nov,

day = "28",

doi = "10.1182/blood-2023-180006",

language = "English",

volume = "142",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Supplement 1 - 342",

}

Smits, F, Groen, K, Levin, MD, Stege, C, Van Kampen, RJW, Van der Spek, E, Bilgin, YM, Thielen, N, Nijhof, IS, Ludwig, I, De Waal, EGM, Sandberg, Y, Kentos, A, Timmers, GJ, Regelink, JC, Westerman, M, de Heer, K, Vekemans, MC, Durdu-Rayman, N, de Graauw, N, Seefat, MR, van de Donk, NWCJ, Ypma, PF, Nasserinejad, K & Zweegman, S 2023, 'Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study', Blood, vol. 142, no. Supplement 1 - 342. https://doi.org/10.1182/blood-2023-180006

TY - JOUR

T1 - Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

AU - Smits, F

AU - Groen, K

AU - Levin, MD

AU - Stege, C

AU - Van Kampen, RJW

AU - Van der Spek, E

AU - Bilgin, YM

AU - Thielen, N

AU - Nijhof, IS

AU - Ludwig, I

AU - De Waal, EGM

AU - Sandberg, Y

AU - Kentos, A

AU - Timmers, GJ

AU - Regelink, JC

AU - Westerman, M

AU - de Heer, K

AU - Vekemans, MC

AU - Durdu-Rayman, N

AU - de Graauw, N

AU - Seefat, MR

AU - van de Donk, NWCJ

AU - Ypma, PF

AU - Nasserinejad, K

AU - Zweegman, S

PY - 2023/11/28

Y1 - 2023/11/28

N2 - The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories ‘fit’, ‘intermediate-fit’ or ‘frail’. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study.

AB - The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories ‘fit’, ‘intermediate-fit’ or ‘frail’. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study.

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001159306701099&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1182/blood-2023-180006

DO - 10.1182/blood-2023-180006

M3 - Meeting Abstract

SN - 0006-4971

VL - 142

JO - Blood

JF - Blood

IS - Supplement 1 - 342

ER -

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this